REG - Animalcare Group PLC - Equity Raise Post-Transaction Report

AnimalcareAnnouncement

05/12/2024 09:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241205:nRSE9618Oa&default-theme=true

RNS Number : 9618O  Animalcare Group PLC  05 December 2024

 

Animalcare Group plc

("Animalcare", the "Company" or the "Group")

Equity Raise Post-Transaction Report

5 December 2024. In accordance with the Statement of Principles (November
2022) published by the Pre-Emption Group, Animalcare Group Plc (AIM: ANCR),
the international animal health business, announces the following post
transaction report in connection with the Company's non-pre-emptive issue of
equity securities, as announced on 3 December 2024.

Terms defined in the fundraise announcement issued on 3 December 2024 (the
'Fundraise Announcement') have the same meanings in this announcement unless
the context provides otherwise.

 Name of Issuer       Animalcare Group plc
 Transaction Details  The Company issued 8,602,150 new ordinary shares in total pursuant to the
                      Fundraise, representing approximately 14.2% of the Company's existing issued
                      ordinary shares prior to the Fundraise.

                      Settlement and admission of the Placing Shares took place at 8.00 am on 5
                      December 2024.
 Use of Proceeds      As set out in the Fundraise Announcement the proceeds of the Fundraise (net of
                      transaction costs) will be used to part fund the cash consideration payable by
                      the Company for the conditional acquisition of the entire issued share capital
                      of Randlab Pty Ltd, Randlab Australia Pty Ltd (and its wholly-owned
                      subsidiary, Randlab (New Zealand) Limited) and Randlab Middle East Veterinary
                      Medicine Trading Single Owner L.L.C. , a privately-owned Australian-based
                      equine veterinary business (the "Acquisition"). The Fundraise will also
                      enable the Company to maintain an appropriate leverage position that enables
                      Animalcare to continue to invest in its growth strategy, including future
                      inorganic investment opportunities.
 Quantum of Proceeds  The aggregate gross proceeds from the Fundraise amounted to
                      approximately £20 million.
 Discount             The Issue Price of 232.5 pence per Placing Share represented a 5.1% discount
                      to the closing price on 2 December 2024.
 Allocations          Soft pre-emption has been adhered to in the allocations process, where
                      possible. The Company was involved in the allocations process, which has been
                      carried out in compliance with the MIFID II Allocation requirements.
 Consultation         Stifel and the Company undertook a pre-launch wall-crossing process, including
                      consultation with certain major shareholders, to the extent reasonably
                      practicable and permitted by law.
 Retail               Following discussions between Stifel and the Company, it was decided that a
                      retail offer would not be included in the Placing. The Placing structure was
                      chosen to minimise time to completion and complexity.

 

 For further enquiries, please contact:

 Animalcare Group Plc                                                          +44 (0)1904 487 687
 Jenny Winter, Chief Executive Officer
 Chris Brewster, Chief Financial Officer                                       communications@animalcaregroup.com (mailto:communications@animalcaregroup.com)

 Media/investor relations
 Stifel Nicolaus Europe Limited                                                +44 (0) 20 7710 7600

 (Sole and Exclusive M&A Adviser, Sole Bookrunner and Nominated Adviser)
 Ben Maddison

 Charles Hoare

 Nicholas Harland

 Francis North

Forward Looking Statements

Statements that are not historical facts, including statements about
Animalcare or its management's beliefs and expectations, are forward-looking
statements. Forward-looking statements, by their nature, involve substantial
risks and uncertainties as they relate to events and depend on circumstances
which will occur in the future and actual results and developments may differ
materially from those expressly stated or otherwise implied by these
statements.

These forward-looking statements are statements regarding Animalcare's
intentions, beliefs or current expectations concerning, among other things,
its results of operations, financial condition, prospects, growth, strategies
and the industry and markets within which it operates.

These forward-looking statements relate to the date of this announcement and
Animalcare does not undertake any obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after
such date.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIGCBDDGBGDGSU